Company Performance Metrics
- Richard Freed: CEO & Co-Founder
RheumaGen develops a class of cell and gene therapy treatments aimed at autoimmune diseases by editing the human leukocyte antigen immune gene so that the immune system does not attack healthy tissues. The company’s work focuses on designing one-time therapeutic candidates, including programs targeting refractory rheumatoid arthritis and other
autoimmune conditions, and advancing these through preclinical and early clinical development stages. RheumaGen’s pipeline uses HLA gene-editing approaches to alter disease-linked immune responses at their source and explores additional indications where HLA alleles play a role. Its operations include partnerships for drug delivery and manufacturing collaborations to support development of its therapies.
